Literature DB >> 22906633

The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism.

Long Chen1, Yi Xu2, Wei Li3, Hao Wu4, Zhuoka Luo2, Xuehua Li2, Feifei Huang2, Clint Young5, Zheng Liu4, Shuyuan Zhou6.   

Abstract

AIMS: The present work investigated the underlying mechanism for the positive inotropic effect of liguzinediol (LZDO) in isolated rat hearts. MAIN
METHODS: Isolated rat heart perfusion, intracellular action potential recording, patch clamp and Ca2+ imaging were used to measure the isolated rat heart contractility, action potential duration, L-type Ca2+ current and sarcoplasmic reticulum (SR) Ca2+ transient in rat cardiomyocyte, respectively. KEY
FINDINGS: LZDO (1, 10, and 100μM) significantly enhanced the inotropy of isolated rat hearts, but not heart rates. Nimodipine (1μM, an L-type Ca2+ channel antagonist), ruthenium red (5μM, a ryanodine receptor inhibitor) and thapsigargin (2μM, an irreversible SR Ca2+ ATPase inhibitor) completely blocked the positive inotropic effect of LZDO. LZDO significantly enhanced the intracellular Ca2+ transient in rat cardiomyocyte. However, LZDO (100μM) did not increase L-type Ca2+ channel current. Moreover, LZDO (100μM) restored the depletion effect of caffeine on Ca2+ transient. The following compounds also failed to block the positive inotropic effect of LZDO (100μM): β-AR antagonist (propranolol 1μM), phosphodiesterase (PDE) inhibitor (IBMX 5μM), Na+-K+ ATPase inhibitor (ouabain 1μM), α(1)-AR antagonist (prazosin 1μM), dopamine D1 receptor antagonist (SCH23390 1μM) and Na+-Ca2+ exchange inhibitor (KB-R7943 1μM). SIGNIFICANCE: The positive inotropic effect of LZDO in isolated rat hearts was mediated through an elevation of SR Ca2+ transient, which may act on SR Ca2+ ATPase. LZDO has a unique biological mechanism that may prove effective in treating heart failure in clinic.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906633     DOI: 10.1016/j.lfs.2012.08.001

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Hydrogen Sulfide Targets the Cys320/Cys529 Motif in Kv4.2 to Inhibit the Ito Potassium Channels in Cardiomyocytes and Regularizes Fatal Arrhythmia in Myocardial Infarction.

Authors:  Shan-Feng Ma; Yan Luo; Ying-Jiong Ding; Ying Chen; Shi-Xin Pu; Hang-Jing Wu; Zhong-Feng Wang; Bei-Bei Tao; Wen-Wei Wang; Yi-Chun Zhu
Journal:  Antioxid Redox Signal       Date:  2015-03-31       Impact factor: 8.401

2.  Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure.

Authors:  Yu Li; Ping Song; Qing Zhu; Qiu-yi Yin; Jia-wen Ji; Wei Li; Hui-min Bian
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

3.  The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism.

Authors:  Qi Chen; Dini Zhang; Yunhui Bi; Weiwei Zhang; Yuhan Zhang; Qinghai Meng; Yu Li; Huimin Bian
Journal:  Chin Med       Date:  2020-06-15       Impact factor: 5.455

4.  Synthesis, biological evaluation, and pharmacokinetic study of novel liguzinediol prodrugs.

Authors:  Zheng Liu; Wei Li; Hong-Mei Wen; Hui-Min Bian; Jing Zhang; Lei Chen; Long Chen; Kun-Di Yang
Journal:  Molecules       Date:  2013-04-18       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.